Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olsalazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 3/20 | 0.72 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.72 |
| ▸ | ALOX5 known ✓ | P09917 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | BLVRB | P30043 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.85 |
| ▸ | THRB | P10828 | 2/20 | 0.85 |
| ▸ | RECQL | P46063 | 2/20 | 0.85 |
| ▸ | APP | P05067 | 1/20 | 0.85 |
| ▸ | BLM | P54132 | 1/20 | 0.85 |
| ▸ | PHLPP2 | Q6ZVD8 | 4/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olsalazine SCHEMBL29378994 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL2628413 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL29861404 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL29385751 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL25118 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL5922630 | 0.98 | MEN1 (0.96) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL19693100 | 0.98 | MEN1 (0.96) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL2228872 | 0.98 | MEN1 (0.96) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL28138401 | 0.98 | MEN1 (0.96) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL29769 | 0.98 | MEN1 (0.96) | MEN1KMT2AKDRPDE4ABLVRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 17954 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705511-A1 | DNA METHYLATION-BASED ALGORITHM TO DIAGNOSE IRRITABLE BOWEL SYNDROME AND OTHER GI CONDITIONS | The Regents of the University of California (US) | 2026-03-11 | — | — | EP | claimed |
| US-12571795-B2 | Anti-MAA immunoglobulin isotypes in inflammatory bowel disease: novel diagnostic implications for ulcerative colitis | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2026-03-10 | — | — | US | claimed |
| EP-4701663-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-03-04 | — | — | EP | claimed |
| EP-4689191-A2 | METHODS OF CLASSIFYING AND TREATING INFLAMMATORY BOWEL DISEASE | Baylor College of Medicine (US) | 2026-02-11 | — | — | EP | claimed |
| US-20260007611-A1 | ULTRASOUND RESPONSIVE NANOCLUSTER FOR CANCER TREATMENT AND METHOD FOR MANUFACTURING THE SAME | INDUSTRY UNIV COOPERATION FOUNDATION YEUNGNAM UNIV (KR) | 2026-01-08 | — | — | US | claimed |
| WO-2025245006-A1 | EXHALED BREATH OF VOLATILE ORGANIC COMPOUNDS FOR IBD DIAGNOSIS AND MANAGEMENT | THE CLEVELAND CLINIC FOUNDATION (US) | 2025-11-27 | — | — | WO | claimed |
| US-12473370-B2 | TL1A associated antibody compositions and methods of use | Absci Corporation (US) | 2025-11-18 | — | — | US | claimed |
| WO-2025224462-A1 | INFLAMMATORY BOWEL DISEASES | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2025-10-30 | — | — | WO | claimed |
| US-20250332230-A1 | ULCERATIVE COLITIS TREATMENTS IN SELECTED PATIENTS | THERIVA BIOLOGICS INC (US) | 2025-10-30 | — | — | US | claimed |
| US-20250326778-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2025-10-23 | — | — | US | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| US-4559330-A | Use of 3,3'-azo-bis-(6-hydroxy benzoic acid) as a drug and pharmaceutical compositions containing the same | PHARMACIA AB (SE) | 1985-12-17 | — | — | US | claimed |
| US-4528367-A | Method and intermediates for preparing high purity 3,3'-azo-bis-(6-hydroxy benzoic acid) | PHARMACIA AB (SE) | 1985-07-09 | — | — | US | claimed |
| EP-0066861-B1 | DIANIONIC 5,5'-AZOBIS-SALICYLIC-ACID COMPOSITION | PHARMACIA AB (SE) | 1985-03-27 | — | — | EP | claimed |
| EP-0036636-B1 | A METHOD AND INTERMEDIATES FOR PREPARING 3,3'-AZO-BIS-(6-HYDROXY BENZOIC ACID) | PHARMACIA AB (SE) | 1984-02-15 | — | — | EP | claimed |
| EP-0036637-B1 | USE OF 3,3'-AZO-BIS-(6-HYDROXY BENZOIC ACID) AS A DRUG AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | PHARMACIA AB (SE) | 1983-10-19 | — | — | EP | claimed |
| US-4374932-A | 5-ASA Drug delivery system | G. D. SEARLE & CO. (US) | 1983-02-22 | — | — | US | claimed |
| US-4312806-A | ALKALINE EARTH SALT OF 5,5'-AZOBIS-SALICYLIC ACID | G. D. SEARLE & CO. (US) | 1982-01-26 | — | — | US | claimed |
| EP-0036636-A1 | A method and intermediates for preparing 3,3'-azo-bis-(6-hydroxy benzoic acid) | PHARMACIA AB (SE) | 1981-09-30 | — | — | EP | claimed |
| EP-0036637-A1 | Use of 3,3'-azo-bis-(6-hydroxy benzoic acid) as a drug and pharmaceutical compositions containing the same | PHARMACIA AB (SE) | 1981-09-30 | — | — | EP | claimed |